- Previous Close
0.8110 - Open
0.8620 - Bid --
- Ask --
- Day's Range
0.8130 - 0.8990 - 52 Week Range
0.6580 - 17.7500 - Volume
20,642 - Avg. Volume
99,674 - Market Cap (intraday)
3.933M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-15.4900 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
180lifesciences.comRecent News: ATNF
View More
Performance Overview: ATNF
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATNF
View MoreValuation Measures
Market Cap
3.93M
Enterprise Value
-497.36k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.87%
Return on Equity (ttm)
-135.21%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.18M
Diluted EPS (ttm)
-15.4900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.59M
Total Debt/Equity (mrq)
1.67%
Levered Free Cash Flow (ttm)
-3.18M